Side effects that occurred in more than 2% of people treated with alirocumab in clinical trials and that occurred more frequently than with placebo, included nose and throat irritation, injection site reactions and bruising, flu-like symptoms, urinary tract infection, diarrhea, bronchitis and cough, and muscle pain, soreness, and spasms [REF].
There are no available data on use of alirocumab in pregnant women to assess risks to the fetus, nor is there data on use in children [REF].